Health
Novartis cardiovascular drug trial fails to significantly improve patient outcomes
CNBC reports that Novartis's pelacarsen study missed its cardiovascular goal, raising questions about related drug programs.
The short version
- Novartis announced that its clinical trial for pelacarsen failed to significantly improve cardiovascular outcomes.[CNBC]
- Citi analysts noted that the broader Lp(a) hypothesis is weakened rather than disproven, though detailed data remain scarce.[CNBC]
- Novartis stated that complete results from the trial will be presented at an upcoming medical congress.[CNBC]
Key facts
- Novartis announced that its trial for pelacarsen failed to significantly improve cardiovascular outcomes.[CNBC]
- Analysts had previously estimated peak annual sales of roughly $4 billion to $5 billion for pelacarsen if it had been successful.[CNBC]
- Novartis indicated that complete trial findings will be shared during an upcoming medical congress.[CNBC]
What remains uncertain
- Citi analysts cautioned that trial details remain scarce beyond the initial topline miss, leaving the broader Lp(a) hypothesis weakened but not disproven.[CNBC]
Sources
Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.